ABSTRACT
This study is aiming to evaluate the effect and dose of Anoxaparin given to pregnant women with acute venous thromboembolism. This Observational 'prospective' study was carried out at Bab-El Shaareyia university hospital-Cairo-Egypt and Maternity Hospital, Sabbah- Kuwait on 20 pregnant women aged 22-41 years, with acute venous thromboembolism verified by objective means. Patients were treated with Enoxaparin from diagnosis until delivery. Treatment was monitored with anti-activated factor xa [anti-xa] activity, and the dose was adjusted to achieve 0.5-l.0U/ml 2-3 hours post-injection. Non of the patients suffered recurrent venous thromboembolisn or major bleeding complications. In 9 of 13 women starting with conventional dose of Enoxaparin, dose escalation was necessary to reach target anti- xa activity. None of the 6 women who started with Enoxaparin required dose escalation. One women who started with 133iu/kg bd required dose reduction. Bioaccumulaton was not observed. This study suggests that Enoxaparin may be used for the treatment acute venous thromboembolism in pregnancy approximately 10-20% higher doses of Enoxaparin may he needed as compared with non-pregnant individuals